Genetic polymorphisms of tumor necrosis factor-α modify the association between dietary polyunsaturated fatty acids and fasting HDL-cholesterol and apo A-I concentrations

American Journal of Clinical Nutrition

Volumn 86, Issue 3, 2007, Pages 768-774

  Fontaine Bisson, Bénédicte ^a   Wolever, Thomas M S ^a,d   Chiasson, Jean Louis ^b   Rabasa Lhoret, Rémi ^b   Maheux, Pierre ^c   Josse, Robert G ^a,d   Leiter, Lawrence A ^a,d   Rodger, N Wilson ^e   Ryan, Edmond A ^f   Connelly, Philip W ^a,d   Corey, Paul N ^a   El Sohemy, Ahmed ^a,g  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e ST JOSEPH S HEALTH CENTRE   (Canada)

^f ALBERTA ENVIRONMENT AND PARKS   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

Apolipoprotein A I; Genotype; HDL cholesterol; Polyunsaturated fatty acids; Tumor necrosis factor ; Type 2 diabetes

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; POLYUNSATURATED FATTY ACID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIETARY INTAKE; FEMALE; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE;

EID: 34548811406     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/86.3.768     Document Type: Article

References (53)

1. Wijendran V, Hayes KC. Dietary n-6 and n-3 fatty acid balance and cardiovascular health. Annu Rev Nutr 2004;24:597-615.
2. Esteve E, Ricart W, Fernandez-Real JM. Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr 2005;24:16-31.
3. Benatti P, Peluso G, Nicolai R, Calvani M. Polyunsaturated fatty acids: biochemical, nutritional and epigenetic properties. J Am Coll Nutr 2004;23:281-302.
4. Warne J. Tumour necrosis factor alpha: a key regulator of adipose tissue mass. J Endocrinol 2003;177:351-5.
5. Jovinge S, Hamsten A, Tornvall P, et al. Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism 1998;47:113-8.
6. Grimble R, Howell WM, O'Reilly G, et al. The ability of fish oil to suppress tumor necrosis factor alpha production by peripheral blood mononuclear cells in healthy men is associated with polymorphisms in genes that influence tumor necrosis factor alpha production. Am J Clin Nutr 2002;76:454-9.
7. Caughey G, Mantzioris E, Gibson RA, Cleland LG, James MJ. The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr 1996;63:116-22.
8. Vega-Lopez S, Kaul N, Devaraj S, Cai RY, German B, Jialal I. Supplementation with omega3 polyunsaturated fatty acids and all-rac alphatocopherol alone and in combination failed to exert an anti-inflammatory effect in human volunteers. Metabolism 2004;53:236-40.
9. Meydani S, Lichtenstein AH, Cornwall S, et al. Immunologic effects of national cholesterol education panel step-2 diets with and without fish-derived N3 fatty acid enrichment. J Clin Invest 1993;92:105-13.
10. Ryden M, Arvidsson E, Blomqvist L, Perbeck L, Dicker A, Arner P. Targets for TNF-alpha-induced lipolysis in human adipocytes. Biochem Biophys Res Commun 2004;318:168-75.
11. Grunfeld C, Verdier JA, Neese R, Moser AH, Feingold KR. Mechanisms by which tumor necrosis factor stimulates hepatic fatty acid synthesis in vivo. J Lipid Res 1988;29:1327-35.
12. Van Der Poll T, Romijn JA, Endert E, Borm JJJ, Buller HR, Sauerwein HP. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am J Physiol 1991;261:E457-65.
13. Svenungsson E, Gunnarsson I, Fei GZ, Lundberg IE, Klareskog L, Frostegard J. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with upregulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 2003;48:2533-40.
14. Semb H, Peterson J, Tavernier J, Olivecrona T. Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J Biol Chem 1987;262:8390-4.
15. Kim M, Sweeney TR, Shigenaga JK, et al. Tumor necrosis factor and interleukin 1 decrease RXRα, PPARα, PPARγ, LXRα, and the coactivators SRC-1, PGC-1α, and PGC-1β in liver cells. Metabolism 2007;56:267-79.
16. Navarro M, Carpintero R, Acin S, et al. Immune-regulation of the apolipoprotein A-I/C-III/A-IV gene cluster in experimental inflammation. Cytokine 2005;31:52-63.
17. Duan H, Li Z, Mazzone T. Tumor necrosis factor-alpha modulates monocyte/macrophage apoprotein E gene expression. J Clin Invest 1995;96:915-22.
18. Ly H, Francone OL, Fielding CJ, et al. Endotoxin and TNF lead to reduced plasma LCAT activity and decreased hepatic LCAT mRNA levels in Syrian hamsters. J Lipid Res 1995;36:1254-63.
19. Kaluza W, Reuss E, Grossmann S, et al. Different transcriptional activity and in vitro TNF-alpha production in psoriasis patients carrying the TNF-alpha 238A promoter polymorphism. J Invest Dermatol 2000;114:1180-3.
20. Kroeger K, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism affects transcription. Mol Immunol 1997;5:391-9.
21. Koss K, Satsangi J, Fanning GC, Welsh KI, Jewell DP. Cytokine (TNF alpha, LT alpha and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies Genes Immun 2000;1:185-90.
22. Hotamisligil G. Inflammation and metabolic disorders. Nature 2006;444:860-7.
23. Sniderman A, Blank D, Zakarian R, Bergeron J, Frohlich J. Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula. Clin Biochem 2003;36:499-504.
24. Fontaine-Bisson B, Wolever TMS, Chiasson JL, et al. TNF-α 238G>A genotype alters post-prandial plasma levels of free fatty acids in obese individuals with type 2 diabetes. Metabolism 2007;56:649-55.
25. Health Canada. Canadian nutrient file. Ottawa, Canada: Health Protection Branch, 1997.
26. Kriska A. Modifiable activity questionnaire. In: A collection of physical activity questionnaires for health-related research. Med Sci Sports Exerc 1997;29:S73-8.
27. Barrett J, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5.
28. Willet W. Nutritional epidemiology. 2nd ed. New York, NY: Oxford University Press, 1998.
29. Harris W. Fish oil and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res 1989;30:785-807.
30. Sanders T. Polyunsaturated fatty acids and coronary heart disease. Baillieres Clin Endocrinol Metab 1990;4:877-94.
31. Dewailly EE, Blanchet C, Gingras S, et al. Relations between n-3 fatty acid status and cardiovascular disease risk factors among Quebecers. Am J Clin Nutr 2001;74:603-11.
32. Jin W, Sun GS, Marchadier D, Octtaviani E, Glick JM, Rader DJ. Endothelial cells secrete triglyceride lipase and phospholipase activities in response to cytokines as a result of endothelial lipase. Circ Res 2003;92:644-50.
33. Khovidhunkit W, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. Endotoxin down-regulates ABCG5 and ABCG8 in mouse liver and ABCA1 and ABCG1 in J774 murine macrophages: differential role of LXR. J Lipid Res 2003;44:1728-36.
34. Khovidhunkit W, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. Regulation of scavenger receptor class B type I in hamster liver and Hep3B cells by endotoxin and cytokines. J Lipid Res 2001;42:1636-44.
35. Zannis V, Chroni A, Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med 2006;84:276-94.
36. Popa C, Netea MG, Radstake T, et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005;64:303-5.
37. Maziere C, Conte MA, Degonville J, Ali D, Maziere JC. Cellular enrichment with polyunsaturated fatty acids induces an oxidative stress and activates the transcription factors AP1 and NFkappaB. Biochem Biophys Res Commun 1999;265:116-22.
38. Epstein F. Nuclear factor-kB - a pivotal transcription factor in chronic inflammatory disease. N Engl J Med 1997;336:1066-71.
39. Trebble T, Arden NK, Stroud MA, et al. Inhibition of tumour necrosis factor-alpha and interleukin 6 production by mononuclear cells following dietary fish-oil supplementation in healthy men and response to antioxidant co-supplementation. Br J Nutr 2003;90:405-12.
40. Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989;320:265-71.
41. Turek J, Schoenlein IA, Clark LK, Van Alstine WG. Dietary polyunsaturated fatty acid effects on immune cells of the porcine lung. J Leukoc Biol 1994;56:599-604.
42. Lokesh B, Sayers TJ, Kinsella JE. Interleukin-1 and tumor necrosis factor synthesis by mouse peritoneal macrophages is enhanced by dietary n-3 polyunsaturated fatty acids. Immunol Lett 1990;23:281-5.
43. Rusyn I, Bradham CA, Cohn L, et al. Corn oil rapidly activates nuclear factor-kappaB in hepatic Kupffer cells by oxidant-dependent mechanisms. Carcinogenesis 1999;20:2095-100.
44. Novak T, Babcock TA, Jho DH, Helton WS, Espat NJ. NF-kappa B inhibition by omega-3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am J Physiol Lung Cell Mol Physiol 2003;284:L84-9.
45. Zeyda M, Saemann MD, Stuhlmeier KM, et al. Polyunsaturated fatty acids block dendritic cell activation and function independently of NF-kappaB activation. J Biol Chem 2005;280:14293-301.
46. Tappia P, Man WJ, Grimble RF. Influence of unsaturated fatty acids on the production of tumour necrosis factor and interleukin-6 by rat peritoneal macrophages. Mol Cell Biochem 1995;143:89-98.
47. Karsten S, Schafer G, Schauder P. Cytokine production and DNA synthesis by human peripheral lymphocytes in response to palmitic, stearic, oleic, and linoleic acid. J Cell Physiol 1994;161:15-22.
48. Wallace F, Miles EA, Calder PC. Activation state alters the effect of dietary fatty acids on pro-inflammatory mediator production by murine macrophages. Cytokine 2000;12:1374-9.
49. Renz H, Gong JH, Schmidt A, Nain M, Gemsa D. Release of tumor necrosis factor-alpha from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides. J Immunol 1988;141:2388-93.
50. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000;49:497-505.
51. Fruchart J, Staels B, Duriez P. PPARS, metabolic disease and atherosclerosis. Pharmacol Res 2001;44:345-52.
52. Xu J, Chavis JA, Racke MK, Drew PD. Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J Neuroimmunol 2006;176:95-105.
53. Tanaka T, Itoh H, Doi K, et al. Down regulation of peroxisome proliferator-activated receptor γ expression by inflammatory cytokines and its reversal by thiazolidinediones. Diabetologia 1999;42:702-10.